Adial Pharmaceuticals (ADIL) Expected to Release Quarterly Earnings on Wednesday

Adial Pharmaceuticals (NASDAQ:ADIL) is expected to be issuing its Q2 2026 results before the market opens on Wednesday, August 12th. Analysts expect Adial Pharmaceuticals to announce earnings of ($1.0325) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Friday, August 14, 2026 at 4:00 PM ET.

Adial Pharmaceuticals (NASDAQ:ADIL) last issued its earnings results on Friday, May 8th. The company reported ($1.48) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.73) by $1.25.

Adial Pharmaceuticals Stock Performance

Shares of ADIL opened at $3.80 on Wednesday. The stock has a 50-day moving average of $2.72 and a two-hundred day moving average of $2.60. The stock has a market cap of $8.13 million, a P/E ratio of -0.48 and a beta of 1.39. Adial Pharmaceuticals has a one year low of $1.31 and a one year high of $11.47.

Analyst Ratings Changes

ADIL has been the subject of several research analyst reports. Alliance Global Partners initiated coverage on Adial Pharmaceuticals in a research note on Monday. They issued a “buy” rating and a $11.00 price objective for the company. Loop Capital set a $6.00 price target on shares of Adial Pharmaceuticals in a report on Monday, June 15th. Needham & Company LLC lowered shares of Adial Pharmaceuticals to a “buy” rating in a research report on Monday, June 15th. Weiss Ratings restated a “sell (e+)” rating on shares of Adial Pharmaceuticals in a research note on Friday, July 17th. Finally, Brookline Capital Markets cut shares of Adial Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, June 11th. Three research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $15.62.

Insider Buying and Selling at Adial Pharmaceuticals

In related news, major shareholder Coastlands Capital Lp acquired 25,000 shares of Adial Pharmaceuticals stock in a transaction on Monday, June 29th. The stock was acquired at an average price of $2.60 per share, for a total transaction of $65,000.00. Following the purchase, the insider owned 373,322 shares of the company’s stock, valued at approximately $970,637.20. This represents a 7.18% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In the last ninety days, insiders bought 36,753 shares of company stock worth $97,638. Company insiders own 1.86% of the company’s stock.

Institutional Trading of Adial Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Armistice Capital LLC purchased a new position in Adial Pharmaceuticals during the fourth quarter valued at approximately $562,000. Jane Street Group LLC lifted its holdings in Adial Pharmaceuticals by 887.3% in the fourth quarter. Jane Street Group LLC now owns 121,841 shares of the company’s stock valued at $27,000 after acquiring an additional 109,500 shares during the period. Finally, Citadel Advisors LLC purchased a new stake in Adial Pharmaceuticals in the 3rd quarter worth approximately $51,000. 16.41% of the stock is owned by institutional investors and hedge funds.

Adial Pharmaceuticals Company Profile

Adial Pharmaceuticals, Inc, incorporated in Delaware and founded in 2003, is a clinical-stage specialty pharmaceutical company dedicated to the development of treatments for addiction disorders and central nervous system conditions. The company’s mission centers on creating novel modalities designed to enhance patient adherence and clinical outcomes, particularly in areas of high unmet medical need. Adial leverages sustained-release delivery technologies to address the challenges associated with oral medication regimens in addiction therapy.

The company’s lead product candidate, AD04, is a bioerodible subcutaneous implant engineered to deliver naltrexone continuously over a multi-month period for individuals with alcohol dependence.